RNAi News GenomeWeb News Premium Content Existing subscribers login here. New to RNAi News? For a trial subscription click here.

Pfizer Plans for First In-House RNAi Rx IND
By 2011 as It Evaluates All Technologies

[September 11, 2008]

By Doug Macron

Having recently completed its acquisition of Coley Pharmaceutical, which specialized in modulating immune responses for therapeutic applications, Pfizer also sees the potential for combining RNAi with immune stimulation within a single drug.

Login | Subscribe